فوستمساویر (Persian Wikipedia)
Analysis of information sources in references of the Wikipedia article "فوستمساویر" in Persian language version.
refsWebsite
Global rank
Persian rank
3,984th place
1,143rd place
18th place
50th place
615th place
1,007th place
businesswire.com
- "ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available" (Press release). ViiV Healthcare. 2 July 2020. Retrieved 2 July 2020 – via Business Wire.
canada.ca
- "Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Retrieved 28 May 2022.
doi.org
- Lai YT, Wang T, O'Dell S, Louder MK, Schön A, Cheung CS, et al. (January 2019). "Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry". Nature Communications. 10 (1): 47. Bibcode:2019NatCo..10...47L. doi:10.1038/s41467-018-07851-1. PMC 6318274. PMID 30604750.
europa.eu
ema.europa.eu
- "Rukobia EPAR". آژانس دارویی اروپا (EMA). 9 December 2020. Retrieved 12 February 2021.
ec.europa.eu
- "Rukobia Product information". Union Register of medicinal products. Retrieved 3 March 2023.
fda.gov
- "FDA Approves New HIV Treatment for Patients With Limited Treatment Options". U.S. Food and Drug Administration (Press release). 2 July 2020. Retrieved 2 July 2020.
This article incorporates text from this source, which is in the public domain.
harvard.edu
ui.adsabs.harvard.edu
- Lai YT, Wang T, O'Dell S, Louder MK, Schön A, Cheung CS, et al. (January 2019). "Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry". Nature Communications. 10 (1): 47. Bibcode:2019NatCo..10...47L. doi:10.1038/s41467-018-07851-1. PMC 6318274. PMID 30604750.
hres.ca
hpr-rps.hres.ca
- "Summary Basis of Decision (SBD) for Rukobia". Health Canada. 23 October 2014. Retrieved 29 May 2022.
nih.gov
dailymed.nlm.nih.gov
- "Rukobia- fostemsavir tromethamine tablet, film coated, extended release". DailyMed. 2 July 2020. Retrieved 14 July 2020.
ncbi.nlm.nih.gov
- Lai YT, Wang T, O'Dell S, Louder MK, Schön A, Cheung CS, et al. (January 2019). "Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry". Nature Communications. 10 (1): 47. Bibcode:2019NatCo..10...47L. doi:10.1038/s41467-018-07851-1. PMC 6318274. PMID 30604750.
pubmed.ncbi.nlm.nih.gov
- Lai YT, Wang T, O'Dell S, Louder MK, Schön A, Cheung CS, et al. (January 2019). "Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry". Nature Communications. 10 (1): 47. Bibcode:2019NatCo..10...47L. doi:10.1038/s41467-018-07851-1. PMC 6318274. PMID 30604750.
tga.gov.au
- "Rukobia". Therapeutic Goods Administration (TGA). 23 July 2021. Retrieved 5 September 2021.